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Comparative study of pulpal responses to pulpotomy with
ProRoot MTA®, RetroMTA®, and TheraCal® in dogs’ teeth
Haewon Lee
Department of Dentistry
The Graduate School, Yonsei University
(Directed by Professor Je Seon Song)
This study was conducted to evaluate and compare pulpal responses to ProRoot 
MTA®, RetroMTA®, and TheraCal® in dog partial pulpotomy models.
Partial pulpotomies were performed on 60 beagle teeth. The exposed pulp 
tissues were randomly capped with either ProRoot MTA® (n=15), RetroMTA®
(n=15),TheraCal® (n=15), or interim restorative material as a negative control 
(n=15). After 4 weeks, the teeth were extracted and processed for histologic and 
vi
immunohistochemical(IHC) examinations using osteocalcin(OC) and dentin 
sialoprotein(DSP). Calcific barrier formation, inflammatory reaction, and the 
odontoblastic layer were evaluated and scored in a blind manner. The areas of 
newly formed calcific barriers were measured for each group. 
In most of the ProRoot MTA® and RetroMTA® specimens, continuous calcific 
barriers were formed, and the pulps contained palisading patterns in the 
odontoblastic layer that were free of inflammation. However, the TheraCal®
specimens had lower quality calcific barrier formation, extensive inflammation, 
and less favorable odontoblastic layer formation. Overall, areas of newly formed 
calcific barrier were higher in the ProRoot MTA® and RetroMTA® specimens than 
in the TheraCal® specimens. Also, IHC revealed that OC and DSP were more 
clearly visible in the ProRootMTA® and RetroMTA® specimens than in the 
TheraCal® specimens. 
RetroMTA® could provide an alternative to ProRoot MTA®. Both materials 
produced favorable pulpal responses that were similar in nature, whereas 
TheraCal® produced less favorable pulpal responses.
Key words : Mineral trioxide aggregate, partial pulpotomy, pulpal response, pulpal 
inflammation, calcific barrier, odontoblastic layer
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I. Introduction
The key factor in vital pulp therapy, such as pulp capping and pulpotomy, is to 
maintain the pulp vitality by protecting the exposed pulp with a biocompatible material. 
Ideally, the exposed pulpal surface under the capping agent is enclosed by the formation 
of a calcific barrier, leaving the apical portion of the pulp free of inflammation. 
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The classical method of vital pulp therapy is performed with calcium hydroxide 
[Ca(OH)2]. However, using Ca(OH)2 has several limitations, including its high solubility
and unpredictable treatment outcomes (Cox et al., 1996; Mente et al., 2014). With the 
introduction of mineral trioxide aggregate (MTA), a novel pulp treatment agent, the short-
term and long-term success rates in vital pulp therapy has increased up to 93% (Leye 
Benoist et al., 2012) and 85% (Mente et al., 2014), respectively. MTA has been recognized 
as a biocompatible material that produces excellent induction of hard-tissue formation 
(Parirokh and Torabinejad, 2010b; Torabinejad and Parirokh, 2010). However, conventional 
MTA (ProRoot MTA®) has disadvantages, such as a long setting time (4 hours) and tooth 
discoloration (Felman and Parashos, 2013;Parirokh and Torabinejad, 2010b), that have led 
to the development of MTA-like materials with improved physical properties.
Biodentine (Septodont, Saint Maur des Fosses, France) has been introduced as an 
alternative MTA-like material with a reduced setting time, better physical properties, and 
ease of handling. Biodentine is compatible with dental pulp cells and stimulated the 
formation of tertiary dentin in vitro (Perard et al., 2013; Zanini et al., 2012). It also induced 
differentiation of cultured pulp cells into odontoblast-like cells (Laurent et al., 2012). An in 
vivo study demonstrated that Biodentine is tissue compatible and promotes mineralized 
tissue bridge formation with comparable morphology and integrity to those produced by 
ProRoot MTA® (De Rossi et al., 2014). Similar results are being achieved with other MTA 
materials such as Angelus MTA (Angelus, Londrina, PR, Brazil), Bioaggregate (Innovative 
BioCeramix, Vancouver, Canada) and MM-MTA (Micromega, Besançon, France).
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RetroMTA® (Meta Biomed Co., LTD, Seoul, Korea) consists of a hydraulic calcium 
zirconia complex that has a setting time of 150 seconds. According to the manufacturer, 
RetroMTA® consists of calcium carbonate [60–80 percent by weight (wt%)], silicon 
dioxide (5–15 wt%), aluminum oxide (5–10 wt%), and calcium zirconia complex (20–30 
wt%) (http://www.biomta.com). Despite the increase in use of RetroMTA® as a vital pulp 
therapy agent, there is limited information about RetroMTA® in the literature.
TheraCal® (Bisco Inc, Schamburg, IL, USA) is a light-cured, resin-modified calcium 
silicate filled liner designed for use in various vital pulp therapies (Gandolfi et al., 2012). 
TheraCal® consists of type III Portland cement (45 wt%), radiopacific material (10 wt%), 
fumed silica (5 wt%) and resin (40 wt%) (Suh et al., 2008). According to an in vitro study 
on resin-based liners, TheraCal® has been introduced as a low cytopathic light-cured liner 
(Hebling et al., 2009). Moreover, TheraCal® has been reported to have higher calcium 
release, a less alkaline pH, and lower solubility when compared to ProRoot MTA or 
Dycal (Gandolfi et al., 2012). Although TheraCal® has already been in use as an effective 
protective liner, to the best of our knowledge, the biological effect of TheraCal® in vivo
has not yet been investigated.
This study was conducted to evaluate and compare calcific barrier formation, 
inflammation, and odontoblastic layer formation of ProRoot MTA®, RetroMTA® and 
TheraCal® in dog pulpotomy models.
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II. Materials and Methods
1. Animal Model
Six male beagle dogs were chosen for this study. Each animal weighed 12 kg and was 
18 months old. The animals had intact dentition and a healthy periodontium. Animal 
selection, management, surgical protocol, and preparation were carried out according to 
routine procedures approved by the Institutional Animal Care and Use Committee, Yonsei 
Medical Center, Seoul, Korea (certification #2013-0153).
2. Surgical Protocol
The surgical procedures were performed under general anesthesia in a sterile operating 
room. The animals received a preanesthetic intravascular injection of Tramadol (1 mg/kg; 
Kwangmyung Pharmaceutical Co., Seoul, Korea) and an intramuscular injection of 
xylazine (0.2 mg/kg; Rompun, Bayer Korea, Seoul, Korea) and Zoletil (5 mg/kg; Ketalar, 
Yuhan, Seoul, Korea). Isoflurane (Gerolan, Choongwae Pharmaceutical Co., Seoul, Korea) 
was administered as inhalation anesthesia. In order to prevent infection, a subcutaneous 
injection of Enrofloxacin (5 mg/kg) was given just before and after treatment and 
intraoral amoxicillin clavulanate (12.5 mg/kg) was given for 5-7 days post-op.
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3. Partial Pulpotomy Procedure
After disinfection of the surgical site, infiltration anesthesia was administered using 
lidocaine (2% lidocaine hydrochloride with epinephrine 1:100,000; Kwangmyung 
Pharmaceutical Co., Seoul, Korea). Sixty teeth, including incisors, canines, and premolars, 
of each animal were allocated randomly to four pulpotomy treatment groups (n=15 per 
group): ProRoot MTA®, RetroMTA®, TheraCal®, and interim restorative material (IRM). 
Initially, the coronal pulp was removed after occlusal reduction in each root canal system 
using a high-speed carbide bur No. 330 (H7 314 008, Brasseler, Germany) and distilled 
water spray. The exposure was then rinsed with sterile saline, and hemostasis was 
achieved by placing a cotton pellet moistened with normal saline over the exposure site 
for 2 minutes. ProRoot MTA®, RetroMTA®, and IRM were each mixed according to the 
manufacturer’s recommendations and placed over the exposure. TheraCal® was placed 
over the exposure in 0.5–1 mm thickness and light-cured for 20 seconds. The remainder 
of the cavity preparation was restored with Ketac Molar (3M ESPE, St. Paul, MN), a self-
curing glass ionomer cement. The dogs were sacrificed 4 weeks after surgery.
4. Histological Analysis
The teeth were removed using extraction forceps and the apical third of each root was 
sectioned with a high-speed bur to facilitate fixation in 10% buffered formalin (Sigma, 
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MO, USA) for 1 day. After fixation, the teeth were decalcified with 10% EDTA (pH 7.4; 
Fisher Scientific, TX, USA) for 6 weeks and embedded in paraffin. Sagittal sections were 
cut at a thickness of 3μm. Sections were deparaffinized and stained with hematoxylin and 
eosin (HE). They were imaged with an optical microscope (Olympus BX40, Olympus Co., 
Tokyo, Japan). Images of the HE stained sections were captured with a CCD digital 
camera (Infinity 2.0, Lumenera Co., Ottawa, Ontario, Canada) and digitized using image 
analyzer software (InnerView 2.0, iNNERViEW Co., Seongnam-Si, Gyeonggi-do, Korea). 
The HE sections were evaluated by three experienced examiners (Y. Shin, H. Lee, and 
JS. Song) in a blind manner. The calcific barrier formation, pulp inflammation, and 
odontoblastic layer were graded according to criteria that were based on a modified 
scoring system adapted from Nowicka et al. as described in Table 1. A final score was 
decided by the three examiners. Also, the areas of newly formed hard-tissue were 
measured using Image J (ver.1.48, National Institute of Health, Bethesda, Maryland, 
USA).
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Table 1. Scores used during histological analysis of calcific barriers and dental pulp
Scores Calcific barrier continuity
1 Complete dentin bridge formation
2
Partial/incomplete dentin bridge formation extending to more than one-half of the 
exposure site but not completely closing the exposure site
3
Initial dentin bridge formation extending to not more than one-half of the 
exposure site
4 No dentin bridge formation
Scores Calcific barrier morphology
1 Dentin or dentin associated with irregular hard tissue
2 Only irregular hard tissue deposition
3 Only a thin layer of hard tissue deposition
4 No hard tissue deposition
Scores Tubules in calcific barrier
1 No tubules present
2 Mild (tubules present in less than 30% of calcific barrier)
3 Moderate to severe (tubules present in more than 30% of calcific barrier)
Scores Inflammation intensity
1 Absent or very few inflammatory cells
2 Mild (an average of <10 inflammatory cells)
3 Moderate (an average of 10–25 inflammatory cells)
4 Severe (an average >25 inflammatory cells)
Scores Inflammation extensity
1 Absent
2 Mild (inflammatory cells next to dentin bridge or area of pulp exposure only)
3
Moderate (inflammatory cells observed in one-third or more of the coronal pulp 
or in the midpulp)
4 Severe (all of the coronal pulp is infiltrated or necrotic)
Scores Inflammation type
1 No inflammation
2 Chronic inflammation
3 Acute and chronic inflammation
4 Acute inflammation
Scores Dental pulp congestion
1 No congestion
2 Mild (enlarged blood vessels next to dentin bridge or area of pulp exposure only)
3
Moderate (enlarged blood vessels observed in one-third or more of the coronal 
pulp or in the midpulp)
4 Severe (all of the coronal pulp is infiltrated with blood cells)
Scores Odontoblastic cell layer
1 Palisade pattern of cells
2 Presence of odontoblast cells and odontoblast-like cells
3 Presence of odontoblast-like cells only
4 Absent
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5. Immunohistochemistry
For immunohistochemistry (IHC), 3 μm sections were deparaffinized in xylene, 
rehydrated, and rinsed with distilled water. For antigen retrieval, protease K (Dako, 
Carpinteria, CA, USA) was used in osteocalcin (OC) and dentin sialoprotein (DSP) staining. 
Endogenous peroxidase activity was quenched by the addition of 3% hydrogen peroxide. 
Sections were incubated in 5% bovine serum albumin (Sigma, MO, USA) to block 
nonspecific binding, and incubated with primary antibody overnight. For OC staining, a 
1:10,000 dilution of the anti-OC antibody (rabbit polyclonal, Ab109112, Abcam, Cambridge, 
UK) was used. For DSP staining, a 1:500 dilution of the anti-DSP antibody (rabbit 
polyclonal, sc-33586; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used. After 
incubation, EnVision+ System-HRP Labelled Polymer anti-rabbit (K4003, Dako North 
America Inc., CA, USA; ready to use) was applied for 20 minutes. Color development was 
performed using labeled streptavidin biotin kits (Dako) according to the manufacturer’s 
instructions. The sections were counterstained with Gill’s hematoxylin (Sigma).
6. Statistical Analysis
Statistical analysis was performed with SPSS (19.0, Chicago, IL, USA). One-way 
ANOVA (p<0.05) and the post-hoc Scheffé test (Bonferroni correction; p<0.017) were 
applied to analyze the area of the newly formed calcific barrier.
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III. Results
We evaluated 13 ProRoot MTA®, 12 RetroMTA®, 12 TheraCal®, and 15 IRM 
specimens histopathologically. The other teeth were excluded from the study because of 
failures during extraction and histopathological processing. The percentage of scores for 
each group is shown in Tables 2, 3, and 4. During sectioning, the specimens with 
amputated pulp tissues were excluded from pulpal inflammation and odontoblastic layer 
evaluation. As shown in Figures 1 and 2, all groups showed better results than IRM in 
terms of calcific barrier formation, inflammatory response, and odontoblastic layer 
formation. However, as can be seen in Figure 3, the TheraCal® group had inferior results 
compared to those of the ProRoot MTA® and RetroMTA® groups. The TheraCal® group 
had relatively incomplete calcific barriers and an unfavorable inflammatory response.
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Table 2. Score percentages for calcific barrier continuity
Table 3. Score percentages for calcific barrier morphology
Groups
Calcific barrier morphology (%)
1 2 3 4
ProRoot MTA® 53.85 (7/13) 38.46 (5/13) ㅡ 7.69 (1/13)
RetroMTA® 41.67 (5/12) 33.33 (4/12) 16.67 (2/12) 8.33 (1/12)
TheraCal® 25 (3/12) 50 (6/12) 25 (3/12) ㅡ
IRM ㅡ 20 (3/15) 6.67 (1/15) 73.33 (11/15)
Table 4. Score percentages for tubules in calcific barrier
Groups
Tubules in calcific barrier (%)
1 2 3
ProRoot MTA® 44.44 (4/9) 44.44 (4/9) 11.11 (1/9)
RetroMTA® 16.67 (1/6) 50 (3/6) 33.33 (2/6)
TheraCal® ㅡ 75 (3/4) 25 (1/4)
IRM ㅡ ㅡ ㅡ
*(number of teeth receiving the score/total number of teeth evaluated)
Groups
Calcific barrier continuity (%)
1 2 3 4
ProRoot MTA® 69.23 (9/13)* 15.38 (2/13) 7.69 (1/13) 7.69 (1/13)
RetroMTA® 50 (6/12) 16.67 (2/12) 25 (3/12) 8.33 (1/12)
TheraCal® 33.33 (4/12) 50 (6/12) 16.67 (2/12) ㅡ
IRM ㅡ 6.67 (1/15) 20 (3/15) 73.33(11/15)
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Figure 1. Histomorphologic characteristics of the newly formed calcific barrier (CB) 
after 4 weeks. A–H shows the characteristics of the CB for each test material in HE 
staining (scale bars=250 µm). (I–L) Dentinal tubules can be seen in higher-magnification 
views (scale bars=100 µm). Red arrows indicate tubules present within newly formed 
CBs, and yellow arrows indicate inflammatory cells.
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Table 5. Score percentages for inflammation intensity and extensity
Groups
Inflammation intensity (%) Inflammation extensity (%)
1 2 3 4 1 2 3 4
ProRoot 
MTA®
81.82 (9/11) * 18.18 (2/11) ㅡ ㅡ 81.82 (9/11) 18.18 (2/11) ㅡ ㅡ
RetroMTA® 72.73 (8/11) 27.27 (3/11) ㅡ ㅡ 72.73 (8/11) 27.27 (3/11) ㅡ ㅡ
TheraCal® 36.36 (4/11) 45.45 (5/11) 18.18 (2/11) ㅡ 36.36 (4/11) 45.45 (5/11) 18.18 (2/11) ㅡ
IRM ㅡ 6.67 (1/15) 46.67 (7/15) 46.67 (7/15) ㅡ 13.33 (2/15) 40 (6/15) 46.67 (7/15)
Table 6. Score percentages for inflammation type and dental pulp congestion
Groups
Inflammation type (%) Dental pulp congestion (%)
1 2 3 4 1 2 3 4
ProRoot 
MTA®
81.82 (9/11) 18.18 (2/11) ㅡ ㅡ 18.18 (2/11) 45.45 (5/11) 36.36 (4/11) ㅡ
RetroMTA® 72.73 (8/11) 27.27 (3/11) ㅡ ㅡ 27.27 (3/11) 36.36 (4/11) 36.36 (4/11) ㅡ
TheraCal® 36.36 (4/11) 63.64 (7/11) ㅡ ㅡ ㅡ 90 (9/10) 10 (1/10) ㅡ
IRM ㅡ 100 (15/15) ㅡ ㅡ ㅡ 22.22 (2/9) 66.67 (6/9) 11.11 (1/9)
Table 7. Score percentages for odontoblastic cell layer
Groups
Odontoblastic cell layer (%)
1 2 3 4
ProRoot MTA® 33.33 (4/12) * 33.33 (4/12) 25 (3/12) 8.33 (1/12)
RetroMTA® 9.09 (1/11) 54.55 (6/11) 27.27 (3/11) 9.09 (1/11)
TheraCal® 9.09 (1/11) 36.36 (4/11) 45.45 (5/11) 9.09 (1/11)
IRM ㅡ ㅡ 27.27 (3/11) 72.73 (8/11)
*(number of teeth receiving the score/total number of teeth evaluated)
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Figure 2. Area of newly formed calcific barrier for each material after 4 weeks. The y-
axis represents the area of calcific barrier (1 × 103 µm2). The bars represent the mean
± standard deviation.
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Figure 3. Immunohistochemical staining of DSP and OC. Red arrows indicate cells with 
a positive signal, and yellow arrows indicate inflammatory cells (scale bars=100 µm).
ProRoot MTA®
Over 69% of the ProRoot MTA® specimens exhibited complete calcific barrier 
formation. These calcific barriers exhibited a lower incidence of tunnel defects (44% mild 
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and 11% moderate) as compared to other groups. The dental pulp in 82% of the ProRoot 
MTA® specimens was found to be free of inflammation. The palisading pattern of the 
odontoblastic cell layer was visible in 33% of the specimens.
RetroMTA®
Complete calcific barrier formation was observed in 50% of the RetroMTA® specimens, 
among which mild (50%) to moderate (33%) tubules were present. The dental pulp in 73% of 
the RetroMTA® specimens was found to be free of inflammation. The palisading pattern 
of the odontoblastic cell layer was visible in only 9% of the specimens, with 55% 
showing odontoblasts and odontoblast-like cells.
TheraCal®
Complete calcific barrier formation was observed in 33% of the TheraCal® specimens. 
Mild tubule formation was observed in 75% of the specimens. The TheraCal® dental pulp 
exhibited mild (45%) to moderate (18%) inflammation, with 90% showing mild dental 
pulp congestion. The palisading pattern of odontoblastic cell layer was visible in only 9% 
of the specimens, with 36% showing odontoblasts and odontoblast-like cells.
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IRM
Complete calcific barrier formation was not observed in any of the IRM specimens, 
with 75% of the specimens having no calcific barriers formed. All IRM specimens 
exhibited chronic inflammation and 50% showed severe intensity and extensity. The 
odontoblastic cell layer was absent in 73% of the specimens.
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IV. Discussion
This study used a dog model to evaluate and compare various pulpal responses of 
different MTA and MTA-like materials using ProRoot MTA® as the gold standard. 
Overall, our study showed favorable results when either ProRoot MTA® or RetroMTA®
was used. These MTAs performed better than TheraCal® when used as partial pulpotomy 
agents. Both ProRoot MTA® and RetroMTA® induced the formation of a complete 
dentinal bridge at the interface with the pulp tissue and controlled the level of 
inflammation underneath.
The high success rates observed with ProRoot MTA® and RetroMTA® in forming a 
calcific barrier could be attributed to their calcium oxide content, which can form calcium 
hydroxide in the presence of water (Faraco and Holland, 2001). Calcium hydroxide has 
been described as a compound that directly affects the microvasculature to reduce the 
plasma outflow, which in turn favors a calcific response in the adjacent pulp tissue 
(Heithersay, 1975). Calcite crystal-like structures have been found close to dentinal 
tubules that were filled with MTA in animal models (Holland et al., 1999). These calcite 
crystals have been known to attract fibronectin, which is responsible for cellular adhesion 
and differentiation (Seux et al., 1991). However, the role of calcific barrier formation is a 
controversial issue, as it does not always equate to healthy pulp tissue. Rather, calcific 
barrier formation should be considered as both a healing process and as a reaction to 
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irritation (Dominguez et al., 2003; Schroder, 1985). The release of calcium from the set 
material stimulates dentin bridge formation and its alkaline pH is known to cause necrosis 
by producing coagulation in contact pulp tissues (Soares, 1996). This reaction may occur 
due to MTA’s high alkalinity, which rises to 12.5 at 3 hours after mixing (Parirokh and 
Torabinejad, 2010a; Torabinejad et al., 1995). The alkaline pH (11.0–12.0) remains high 
for at least 8 weeks after setting in aqueous environment (Fridland and Rosado, 2005), 
and is known to have roles in both inflammation and the induction of a hard-tissue barrier 
by inducing a favorable environment for cell division, matrix formation, and 
antimicrobial activity (Accorinte Mde et al., 2008; Fridland and Rosado, 2005). 
The rate of the calcification reaction could also be a significant factor in vital pulp 
therapy agents. The formation of a calcific bridge does not mean that the pulp will be 
sealed completely from the environment because the bridges are permeable initially. 
Previous studies have reported that connective tissue is present in bridges formed after 
pulpotomy treatment due to the initial disorganized formation of reparative dentin that 
engulfs cellular inclusions (Dominguez et al., 2003). With progression of time and 
mineralization, the permeability decreases and eventually forms a tight seal between the 
pulp and the cavity.
According to the results of this study, RetroMTA® has similar biological features to 
ProRoot MTA® without extensive disadvantages. We found that RetroMTA® resulted in a 
slightly lower pulpal response and smaller mean area of calcific barrier when compared 
with ProRoot MTA®; however, the differences were not statistically significant. 
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RetroMTA® was developed as a bioceramic for root end repair and vital pulp therapy. The 
main advantage of RetroMTA® over ProRoot MTA® includes its reduced setting time and 
absence of heavy metals. The MTA setting time could be a factor that is directly related to 
pulpotomy success. Longer setting times could become a major limitation because the 
MTA material becomes more prone to tissue fluids, leading to material wash out and 
leaching of cytotoxic substances (Camilleri et al., 2005). Despite the advantage of a fast 
setting time, the lower pulpal response of RetroMTA® could be due to differences in the 
manufacturing process and its components. According to the manufacturers, ProRoot 
MTA® is produced through various refining processes for Portland cement, whereas 
RetroMTA® is synthesized by mixing the essential chemical components 
(http://www.biomta.com). A more precise evaluation of each component and their effects 
should be performed.
The absence of complete bridging in TheraCal® group could be related to the lower 
biocompatibility of the material, which causes a higher degree of inflammation. The 
lower biocompatibility of TheraCal® could be attributed to the acrylic monomers in the 
material. Bis-Glycidyl methacrylate (BisGMA) is an acrylic monomer in TheraCal®
that is cytopathic to cultured cells (de Souza Costa et al., 2006; de Souza Costa et al., 
2007;Hanks et al., 1991). BisGMA inhibits glutathione synthesis, one of the major 
intracellular antioxidants, and interferes with the expression of some fundamental 
proteins for pulpal repair such as collagen type I and dentin sialoprotein (Mantellini et 
al., 2003). Moreover, the manufacturer has recommended a depth-of-cure of about 1 
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mm (Griffin Jr, 2012). Despite these guidelines, complete curing of the pulpotomy 
material is difficult to achieve in vivo. The uncured monomer contents leach into the 
pulp and dentinal tubules and have cytotoxic effects on pulpal cells (de Souza Costa et 
al., 2006; Hanks et al., 1994; Pashley et al., 2000). In our study, the prominent tubules 
that were present within the newly formed calcific barriers in teeth treated with 
TheraCal® could have also been the result of exposure to leaching of the uncured 
monomer contents. Consequently, it is not surprising that TheraCal® exhibited less 
favorable pulpal responses in terms of inflammation and calcific barrier formation in 
the pulpotomy models.
In our study, treatment with ProRoot MTA® and RetroMTA® resulted in the up-
regulation of differentiation markers and produced the palisading pattern of odontoblast 
cells. These results indicate that ProRoot MTA® and RetroMTA® have a higher 
odontogenic differentiation potential than TheraCal®. OC is a specific and relatively late-
stage marker of osteoblastic differentiation (Malaval et al., 1994), and DSP is a specific 
marker for odontoblasts and is believed to play a regulatory role in the mineralization of 
reparative dentin (Papagerakis et al., 2002). Many in vitro studies have reported that 
MTAs stimulate dental pulp stem cells to undergo odontogenic differentiation (Hakki et 
al., 2009; Min et al., 2009;Seo et al., 2013). Calcium ions released from MTAs are known 
to play an important role in odontoblastic differentiation, although the precise 
mechanisms underlying MTA-induced odontoblastic differentiation are not completely 
understood (Woo et al., 2013).
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In the present study, a 4-week period was used to evaluate the effects of various MTAs 
on pulp tissues. However, further research may be required because 4 weeks may not be a 
sufficient time period for evaluating the long-term effects of the pulpotomy agents. 
Moreover, the findings of the current study in dogs may not directly correspond to those 
in humans. Therefore, clinical trials using human teeth are necessary for a more accurate
understanding of the materials
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V. Conclusion
In conclusion, this study demonstrated that RetroMTA® may be an alternative to 
ProRoot MTA® because both materials produced similar pulpal responses, whereas 
TheraCal® produced lower calcific barrier formation, higher inflammatory reactions, and 
less favorable odontoblastic layer formation.
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Abstract (in Korean)
개의 치아에서 ProRoot MTA®, RetroMTA® 및 TheraCal®을 이용한
부분치수절단술에 따른 치수반응에 대한 비교연구
연세대학교 대학원 치의학과
이혜원
지도교수: 송제선
본 연구는 개를 이용한 in vivo상의 치아에서 MTA기반의 치수치료재인
ProRoot MTAⓇ, RetroMTAⓇ 및 TheraCalⓇ을 이용한 부분치수절단술 시행 후, 각
재료에 의한 치수 반응을 비교 분석하고자 하였다.
60개의 비글 치아에서 부분치수절단술을 시행하였다. 절단된 치수조직의 상
부는 각각 ProRoot MTAⓇ, RetroMTAⓇ 및 TheracalⓇ을 사용하여 복조되었다. 4주
후 발치된 치아들을 사용하여 조직학적 검사 및 osteocalcin (OC)과 dentin 
sialoprotein (DSP)을 이용한 면역조직화학염색법을 통해, 각 군별로 새롭게 형
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성된 경조직의 양과 질, 치수염증반응의 정도 및 상아모세포층에 대한 분석
및 평가를 시행하였다.
ProRoot MTAⓇ와 RetroMTAⓇ군의 경우 대부분 연속성의 경조직층이 형성되
었으며 치수는 염증반응 없이 잘 배열된 상아모세포층이 관찰되었다. 하지만
TheraCalⓇ군에서 형성된 경조직층은 양과 질적인 면에서 모두 비교적 떨어졌
으며 치수는 심한 염증반응과 잘 배열되지 않은 상아모세포층이 관찰되었다. 
면역조직화학염색결과 역시 OC와 DSP는 ProRoot MTAⓇ와 RetroMTAⓇ군에서
TheraCalⓇ군에서보다 높은 발현율을 보였다. 
결론적으로 TheraCalⓇ는 앞선 두 재료에 비해 치수반응에 있어 열등한 결과
를 나타내었지만, RetroMTAⓇ의 경우 in vivo 상에서 ProRoot MTAⓇ와 유사하게
양호한 치수반응을 나타내어 ProRoot MTAⓇ의 대체재료로 사용될 수 있을 것
으로 기대된다.
핵심되는 말: Mineral trioxide aggregate (MTA), 부분치수절단술, 치수반응, 
치수염증, 경조직형성, 상아모세포층
